Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

Clinically Significant Drug Interactions with Newer Antidepressants

(2011) Edoardo Spina et al.   CNS DRUGS

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antidepressants: Clinically Relevant Drug Interactions to Be Considered

(2010) Rene Schellander et al.   PHARMACOLOGY

A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling

(2009) Akihiro Hisaka et al.   CLINICAL PHARMACOKINETICS